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Hemophagocytic lymphohistiocytosis (HLH) is a rare but severe and often overwhelming sys-
temic hyper-inflammatory syndrome generally presenting with unexplained fevers, hep-
atosplenomegaly, and progressive multi-organ dysfunction. Treatment of HLH has two major
goals: Halting the triggering event and controlling the overactive immune system. However,
patients with primary or recurrent secondary HLH should subsequently undergo allogeneic
HCT for long lasting disease remission. Hereby we present the case of a 69 years old man with
recurrent HLH who underwent a reduced intensity conditioning of fludarabine, cyclophos-
phamide and low dose total body irradiation followed by a haploidentical marrow graft and
post-transplantation cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil as
GVHD prophylaxis. He achieved a durable remission of HLH symptoms despite persistent mye-
loid mixed chimerism.
The use of haploidentical donors and PTCy as tolerance inducing regimen is feasible in HLH. The
achievement of mixed donor chimerism may be enough to control the clinical manifestations
and to cure HLH.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).ute, 12902
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Fig. 1 Serum ferritin levels over the course of haploidentical
transplantation.
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Hemophagocytic lymphohistiocytosis (HLH) is a rare, but
severe and often overwhelming, systemic hyper-
inflammatory syndrome generally presenting with unex-
plained fevers, hepatosplenomegaly, and associated
cytopenias [1]. HLH can involve several organs, including
the liver, lung, skin, and central nervous system, which
commonly leads to multi-organ failure [1]. Laboratory anal-
yses of patients with HLH show findings of hypertriglyc-
eridemia, hypofibrinogenemia, and hyperferritinemia [1].
An elevated level of soluble interleukin (IL)-2 is a biomarker
for HLH [2]. Primary HLH is typically a familiar autosomal
recessive condition that manifests during the 1st year of life
and is caused by mutations in genes that control natural
killer cells and T cell granule-mediated cytotoxic function.
Secondary HLH occurs later in life, with a similar clinical
phenotype in the absence of a known genetic cause. Sec-
ondary HLH arises in the setting of autoimmunity, infection,
malignancy, or, less commonly, may be idiopathic [2,3].
Treatment of HLH has two major goals: (a) to halt the
triggering event and (b) to control the overactive immune
system. In primary HLH, etoposide-based therapy achieves
disease control in most patients; however, eventually,
almost all of them relapse and succumb to the disease.
Given these poor outcomes, patients with primary or recur-
rent secondary HLH receive immune suppression to achieve
HLH remission and subsequently undergo allogeneic
hematopoietic cell transplantation (HCT). The main limita-
tions in the use of allogeneic HCT are timely identification
of a suitable donor and non-relapse mortality.
Case report
A 69-year-old man presented with fever and drenching night
sweats for several weeks. On initial evaluation, a complete
blood count disclosed leukopenia, and computed tomogra-
phy (CT) scans of the chest, abdomen, and pelvis showed
splenomegaly, but no lymphadenopathy. Peripheral blood
flow cytometry and bone-marrow biopsy were unremark-
able. Work up for infection was negative. He underwent a
splenectomy and liver biopsy. Histopathologic evaluation
of the spleen was unremarkable, but the liver biopsy
revealed hemophagocytosis. A serum ferritin level was
7318 ng/mL (30–400). A diagnosis of HLH was made, and
he was started on an HLH-94 treatment regimen [4] consist-
ing of dexamethasone and etoposide, which was followed by
prompt resolution of fevers, improvement of performance
status, and ferritin returning to baseline levels. He com-
pleted 8 weeks of therapy, and his response was maintained
for an additional 7 weeks, after which symptoms of fevers
and night sweats returned, and his serum ferritin increased.
He was restarted on etoposide plus dexamethasone, and
cyclosporin A (CSA) was briefly added to the treatment reg-
imen, but he experienced tremors and altered taste. Subse-
quently, CSA was switched to mycophenolate mofetil
(MMF). He responded to treatment with resolution of fevers,
and was referred for evaluation for an allogeneic HCT. An
unrelated donor search was initiated due to the unavailabil-
ity of siblings, but no suitable unrelated donors werePlease cite this article in press as: Ayala E et al., Haploidentical transplan
histiocytosis in an older adult patient ..., Hematol Oncol Stem Cell Theridentified. As a result, his daughter was used as the donor
source for a haploidentical-donor allograft. We prescribed
a reduced intensity conditioning (RIC) regimen consisting
of 30 mg/m2 fludarabine on Day 6, Day 5, Day 4, Day
3, and Day 214.5 mg/kg/d cyclophosphamide on
Day 6 and Day 5, and 200 cGy total body irradiation on
Day 1, followed by infusion of unstimulated bone-
marrow cells at a dose of 2  108 mononuclear cells/kg
(3.58  106 CD34+ cells/kg). Graft-versus-host disease
(GVHD) prophylaxis consisted of post-transplant cyclophos-
phamide (PTCy) at a dose of 50 mg/kg on Day +3 and Day
+4, and tacrolimus and MMF starting on Day +5 [5]. Early
post-HCT course was complicated with parainfluenza virus
type 3 pneumonia on Day +7. Neutrophil and platelet
engraftment occurred on Day +17 and Day +40, respectively.
Bone-marrow biopsy on Day +35 showed 15% cellularity,
mild histiocytosis, and persistent hemophagocytosis. Donor
chimerism studies showed 50.3% unsorted marrow donor
cells and 66.4% CD3+ and 49.2% CD33+ peripheral blood
donor cells. However, he exhibited no clinical evidence of
HLH other than a serum ferritin level of 5002 ng/mL. MMF
was discontinued on Day +35, and tacrolimus was rapidly
tapered over the subsequent 4 weeks. On Day +68, he devel-
oped Grade II acute GVHD of the skin and gut, which
responded to 1 mg/kg prednisone and tacrolimus. By Day
+180, he was free of clinical manifestations of HLH, but
had developed a cough. Infection work-up showed persis-
tent parainfluenza virus type 3 infection, and lung evalua-
tion revealed bilateral lower lobe infiltrates and
bronchiectasis suggestive of bronchiolitis obliterans and
organizing pneumonia, which responded to steroids. On
Day +416, he was free of symptoms, and his repeated donor
chimerism on peripheral blood analysis at 1 year showed
100% CD3+ and 52% CD33+. Fig. 1 shows serum ferritin levels
over the course of his haploidentical HCT.
Discussion
This case illustrates the efficacy of RIC haploidentical HCT
with PTCy in an adult with recurrent HLH. The patient
remains free of HLH-related organ dysfunction. Addition-
ally, his serum ferritin levels have returned to pre-HCT
baseline values.tation as a promising therapy for relapsed hemophagocytic lympho-
(2016), http://dx.doi.org/10.1016/j.hemonc.2016.05.005
Table 1 Selected published studies of allogeneic HCT for HLH.
Study No. of
patients
HLH type Type Conditioning Graft
failure (%)
Survival
Henter et al. [4] 65 Primary Prospective
multicenter
Busulfan/cyclophosphamide/
etoposide ± ATG
10 62% at 3 y
Baker et al. [8] 91 Primary Retrospective
multicenter
Busulfan/cyclophosphamide/
etoposide + ATG
9 53% at 5 y
Ouachee-Chardin et al. [9] 48 Primary Single center Busulfan/cyclophosphamide/
etoposide + ATG
22 58% at 6 y
Cooper et al. [6] 12 Primary Single center Fludarabine/melphalan/
alemtuzumab
0 75% at 2.5 y
Cesaro et al. [10] 61 Primary Retrospective
multicenter
Busulfan/cyclophosphamide
± etoposide, busulfan/
fludarabine/melphalan, or
busulfan/fludarabine/
thiotepa
5 58% at 8 y
Note. ATG = anti-thymocyte globulin; HCT = hematopoietic cell transplantation; HLH = hemophagocytic lymphohistiocytosis; y = year.
Haploidentical transplantation in an adult patient 3The introduction of allogeneic HCT has dramatically
improved the prognosis of patients with HLH. In HLH-94,
the first prospective multicenter trial for familial HLH,
etoposide-based induction therapy was followed by allo-
geneic HCT, achieving for the first time a remarkable
long-term survival rate of 66% [4]. Current treatment algo-
rithms indicate allogeneic HCT in all patients with familial,
persistent, or recurrent disease, and several published ser-
ies (Table 1) confirmed the results of HLH-94. More
recently, RIC was successfully implemented to decrease
non-relapse mortality associated with the procedure. Graft
failure remains a concern, and recent strategies to improve
engraftment are incorporating in vivo T cell depletion [6,7].
Based on the successful treatment paradigm in children, RIC
allogenic HCT using alternative donors, including umbilical
cord blood units and haploidentical donors, were also used
successfully in familial HLH; however, to our knowledge,
our case represents the first haploidentical HCT for HLH in
a patient of advanced age.
Mixed chimerism occurs in up to half of the patients with
HLH treated with RIC allogenic HCT, and especially if in vivo
T cell depletion is used [6]. Rapid immunosuppression with-
drawal, donor lymphocyte infusions, and stem cell boosts
are used to prevent graft loss [6]. In our case, rapid
immunosuppression withdrawal resulted in achievement of
full donor lymphoid (CD3+), but persistent mixed myeloid
lineage chimerism in peripheral blood. This was associated
with durable resolution of all clinical manifestations of
the disease at the cost of acute GVHD.
In summary, RIC allogeneic HCT using a haploidentical
donor with PTCy as a tolerance-inducing regimen may be
considered in adults with HLH. This experience needs to
be validated in a larger cohort of patients. The achievementPlease cite this article in press as: Ayala E et al., Haploidentical transplan
histiocytosis in an older adult patient ..., Hematol Oncol Stem Cell Therof mixed donor chimerism may be enough to control the
clinical manifestations of HLH.
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